Mounjaro vs Wegovy vs Ozempic — A Korean PT Veteran's Side-by-Side

Why a Trainer Is Writing This

Most comparison pieces between Mounjaro (tirzepatide), Wegovy (semaglutide), and Ozempic (also semaglutide, prescribed for type 2 diabetes off-label for weight) are written by physicians or pharmacists who see the patient at month one and month six. They do not see what happens on the gym floor in months three through twelve, when the scale is winning and the body underneath is quietly losing its scaffolding.

PAFGYM has operated in Gangnam — Seoul's high-end district — for 16 years and accumulated more than 500,000 PT sessions (Gangnam VIP 500K Sessions). The founder holds a Sports Science PhD and is a licensed Physical Therapist. Over the last three years we have trained hundreds of women through every major GLP-1 cycle, and the differences between the drugs become very visible once you watch a client try to do an air squat or a hand-release push-up under each one.

This article does not tell you which drug is "best." That decision belongs to you and your physician. This article tells you what each drug looks like from the muscle and posture side, so the conversation with your doctor is more informed.

Drug Snapshot

The headline difference is mechanism. Semaglutide acts on a single hormonal pathway (GLP-1). Tirzepatide acts on two (GLP-1 and GIP). The dual mechanism translates into greater average weight loss in head-to-head trials — the SURMOUNT-1 trial (NEJM, 2022) reported up to 20.9% body weight reduction at 72 weeks on tirzepatide versus approximately 14.9% on semaglutide in STEP 1.

What Greater Efficacy Looks Like in the Gym

A larger weight drop is not automatically a better outcome for the woman who has to live in her own skin for the next 30 years. From the PAFGYM training floor:

Mounjaro / Zepbound (Tirzepatide)

• Faster, deeper appetite suppression — clients often forget to eat for an entire afternoon
• Higher risk of dropping below the 30 g protein per meal threshold — see our "30g of protein every meal" article for the leucine-mTOR mechanism
• More noticeable facial volume loss in the first 12 weeks — particularly the temporalis and zygomaticus
• Stronger nausea on dose escalation — many clients cannot tolerate strength training in the 48 hours after injection

Wegovy (Semaglutide)

• Slightly more gradual appetite suppression — easier to maintain a structured meal schedule
• Lean-mass loss still present but visually slower — face changes may not appear until month four to six
• More common GI side effects on injection day — clients often need a liquid-protein backup

Ozempic (Off-label for weight)

• Lower starting dose than Wegovy — for many off-label users, milder appetite suppression
• Easier to maintain training volume — but also smaller weight loss per month
• Same lean-mass risk — the underlying mechanism is identical to Wegovy

The Three Numbers That Decide Your Outcome

Regardless of which drug you and your doctor choose, the same three numbers determine whether you finish 12 months as a Rich Slim or a Poor Slim:

1. Protein per meal — 30 g minimum, three times a day, to keep the muscle protein synthesis switch on
2. Strength session count per week — 4 bodyweight sessions of 20 minutes, at 80–90% max heart rate
3. Sleep duration with the 3-3-3 rule — 7.5+ hours, with caffeine cut 10 hours before bed

The University of Chicago sleep restriction study showed that under sleep deprivation, muscle catabolism increases by approximately 60%. Combine that with the appetite suppression of a GLP-1 and a sedentary lifestyle, and the 40% lean-mass loss reported in STEP 1 (and similar numbers in SURMOUNT-1) becomes a near-certainty.

When Each Drug May Be Better Suited (Talk to Your Doctor)

This is general framing only — not medical advice.

• If your primary goal is weight loss volume, tirzepatide (Mounjaro / Zepbound) has the higher ceiling
• If your primary concern is preserving structural muscle and facial volume, semaglutide's gentler ramp may give you a longer window to dial in protein and training
• If you have a personal or family history of medullary thyroid carcinoma or MEN 2, both drug classes are contraindicated per FDA label
• If you are pregnant or trying to conceive, neither drug is appropriate

The Common Mistake: Treating the Drug as the Finish Line

Whichever drug you and your physician select, the single largest mistake we observe on the training floor is the same: clients treat the prescription as the destination instead of the launch ramp. They lose 15–20% of body weight, exit the protocol, and then watch the muscle, the facial volume, and eventually the weight all come back over the following 24 months — a pattern consistent with the ~80% rebound rate in the NWCR registry.

The drug is the attacker. Your aftercare is the defender. Without a defender, the attacker wins the battle and loses the war.

Drugs From Your Doctor, Care From Rich Slim

Rich Slim is the English-language platform built on top of the PAFGYM 16-year, 500,000-session Gangnam protocol. We do not prescribe, dispense, or evaluate GLP-1 drugs. We provide the aftercare system that the drug itself does not — the protein math, the bodyweight progressions, the sleep architecture, the collagen rebuild — so that whichever drug you and your physician choose, the body underneath the scale stays Rich Slim and not Poor Slim.

Drugs from your doctor, care from Rich Slim.

This is not medical advice. Consult your doctor. Individual results vary. This article does not represent FDA-evaluated claims for any GLP-1 product or supplement. Rich Slim does not prescribe, dispense, sell, or refer GLP-1 drugs.